Cerus (CERS) Net Income towards Common Stockholders (2010 - 2026)
Cerus (CERS) reported Net Income towards Common Stockholders of -$1.6 million for Q1 2026, up 78.65% on a YoY basis from -$922488.0 in Q1 2025, and up 24.54% sequentially from -$2.2 million in Q4 2025.
Cerus (CERS) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Cerus (CERS) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$1.6 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 78.65% year-over-year to -$1.6 million; the trailing twelve-month figure through Mar 2026 stood at -$9.6 million (up 48.36% YoY), and the FY2025 full-year result was -$15.6 million, up 23.71% from the prior year.
- Net Income towards Common Stockholders improved to -$1.6 million in Q1 2026, from -$2.2 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$20000.0 in Q3 2025 to a low of -$15.6 million in Q1 2023.
- A 5-year average of -$7.0 million and a median of -$7.3 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders sank 664.08% in 2022 and soared 99.32% in 2025, its largest moves.
- Tracing CERS's Net Income towards Common Stockholders over 5 years: stood at -$14.4 million in 2022, then jumped by 90.37% to -$1.4 million in 2023, then slumped by 51.48% to -$2.1 million in 2024, then retreated by 4.1% to -$2.2 million in 2025, then rose by 24.54% to -$1.6 million in 2026.
- Business Quant data shows CERS's Net Income towards Common Stockholders at -$1.6 million in Q1 2026, -$2.2 million in Q4 2025, and -$20000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.08 Bn | 175.79 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.71 Bn | 125.83 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 108.79 Bn | 99.57 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 68.41 Bn | 66.96 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.34 Bn | 44.67 Bn | 1.29 Bn | - |
| 6 | GE HealthCare Technologies | 28.34 Bn | 26.06 Bn | 1.98 Bn | 411.00 Mn |
| 7 | Dexcom | 28.34 Bn | 27.22 Bn | 750.30 Mn | 199.50 Mn |
| 8 | Smith & Nephew | 26.87 Bn | 26.29 Bn | - | - |
| 9 | Koninklijke Philips | 25.43 Bn | 22.31 Bn | 2.07 Bn | 176.78 Mn |
| 10 | Cerus | 596.99 Mn | 516.56 Mn | 27.89 Mn | -1.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.65 Mn |
| Dec 31, 2025 | -2.18 Mn |
| Sep 30, 2025 | -20,000.00 |
| Jun 30, 2025 | -5.72 Mn |
| Mar 31, 2025 | -7.72 Mn |
| Dec 31, 2024 | -2.10 Mn |
| Sep 30, 2024 | -2.93 Mn |
| Jun 30, 2024 | -5.78 Mn |
| Mar 31, 2024 | -9.69 Mn |
| Dec 31, 2023 | -1.39 Mn |
| Sep 30, 2023 | -7.29 Mn |
| Jun 30, 2023 | -13.33 Mn |
| Mar 31, 2023 | -15.64 Mn |
| Dec 31, 2022 | -14.38 Mn |
| Sep 30, 2022 | -8.52 Mn |
| Jun 30, 2022 | -8.40 Mn |
| Mar 31, 2022 | -12.28 Mn |
| Dec 31, 2021 | 2.55 Mn |
| Sep 30, 2021 | -12.44 Mn |
| Jun 30, 2021 | -15.36 Mn |